NCT06704828 2024-11-26A Phase II Study of SHR-4602 as Montherapy or in Combination With Other Anti-tumor Therapies in Advanced Solid TumorsShanghai Hengrui Pharmaceutical Co., Ltd.Phase 2 Not yet recruiting20 enrolled